Haybittle J L, Brinkley D, Houghton J, A'Hern R P, Baum M
Medical Research Council Trials Office, Cambridge.
BMJ. 1989 Jun 17;298(6688):1611-4. doi: 10.1136/bmj.298.6688.1611.
To identify any excess mortality caused by adjuvant radiotherapy for early breast cancer.
Prospective randomised clinical trial. Two thousand subjects needed for study to have a 90% chance of detecting a difference in survival rate of 7% with 95% significance. Patients were followed up until June 1988, giving follow up of 158-216 months.
A multicentre trial mainly drawing patients from centres in the United Kingdom.
2800 Women presenting with clinical stage I or II carcinoma of the breast from June 1970 to April 1975.
One group of women (n = 1376) had simple mastectomy followed by immediate postoperative radiotherapy (1320 to 1510 rets). The remaining women (n = 1424) had simple mastectomy with subsequent careful observation of the axilla, radiotherapy being delayed until there was obvious progression or recurrence of disease locally.
Increased mortality in patients treated with radiotherapy from causes other than breast cancer.
Survival was measured from time of first treatment to death or last follow up. Deaths from any cause and from specified causes were counted as events. Comparison over the whole follow up showed a slight excess mortality in the group treated with radiotherapy (relative risk 1.04; 95% confidence interval 0.94 to 1.15). The relative risk of death from breast cancer was 0.97 (0.87 to 1.08) but that of death from other causes was 1.37 (1.09 to 1.72), the increase mainly being in women who had had tumours of the left breast (1.61 (1.17 to 2.24)) and had been treated with orthovoltage (1.85 (1.27 to 2.71)). Analysis of causes of death after five years showed a relative risk of 2.11 (1.25 to 3.59) for new malignancies and of 1.65 (1.05 to 2.58) for cardiac disease, the increase in cardiac mortality being most pronounced in patients who had had tumours of the left breast and whose treatment had included orthovoltage radiation (relative risk 2.67 (1.28 to 5.55)).
Adjuvant radiotherapy after simple mastectomy for early breast cancer produces a small excess late mortality from other cancers and cardiac disease. The risk has to be balanced against the higher risk of local recurrence when immediate postoperative radiotherapy is not given. The balance has to be assessed for each patient, and for many patients radiotherapy will still be desirable in the initial treatment of their early breast cancer.
确定早期乳腺癌辅助放疗所导致的任何额外死亡率。
前瞻性随机临床试验。该研究需要2000名受试者,以便有90%的机会检测出7%的生存率差异,显著性水平为95%。对患者进行随访直至1988年6月,随访时间为158 - 216个月。
一项多中心试验,主要从英国各中心招募患者。
1970年6月至1975年4月期间出现临床I期或II期乳腺癌的2800名女性。
一组女性(n = 1376)接受单纯乳房切除术后立即进行术后放疗(1320至1510伦琴)。其余女性(n = 1424)接受单纯乳房切除术,随后仔细观察腋窝,放疗推迟至疾病出现明显进展或局部复发。
放疗患者因乳腺癌以外原因导致的死亡率增加。
从首次治疗时间至死亡或最后一次随访来测量生存率。将任何原因导致的死亡和特定原因导致的死亡计为事件。在整个随访期间的比较显示,放疗组的死亡率略有增加(相对风险1.04;95%置信区间0.94至1.15)。乳腺癌死亡的相对风险为0.97(0.87至1.08),但其他原因导致死亡的相对风险为1.37(1.09至1.72),增加主要发生在左乳肿瘤患者(1.61(1.17至2.24))以及接受过深部X线治疗的患者(1.85(1.27至2.71))中。对五年后的死亡原因分析显示,新发恶性肿瘤的相对风险为2.11(1.25至3.59),心脏病的相对风险为1.65(1.05至2.58),心脏病死亡率的增加在左乳肿瘤且治疗包括深部X线放疗的患者中最为明显(相对风险2.67(1.28至5.55))。
早期乳腺癌单纯乳房切除术后的辅助放疗会导致其他癌症和心脏病的晚期死亡率略有增加。这种风险必须与不进行术后立即放疗时局部复发的较高风险相权衡。必须为每位患者评估这种权衡,对于许多患者而言,放疗在其早期乳腺癌的初始治疗中仍然是可取的。